Price T Rowe Associates Inc Akebia Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 126,648 shares of AKBA stock, worth $253,296. This represents 0.0% of its overall portfolio holdings.
Number of Shares
126,648
Previous 59,900
111.43%
Holding current value
$253,296
Previous $110,000
18.18%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding AKBA
# of Institutions
112Shares Held
55MCall Options Held
554KPut Options Held
246K-
Black Rock Inc. New York, NY11.6MShares$23.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.28MShares$18.6 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$11.5 Million11.5% of portfolio
-
Geode Capital Management, LLC Boston, MA4.54MShares$9.07 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA4.06MShares$8.13 Million0.01% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $368M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...